Notícias e Atividades da Soleno Therapeutics

Soleno Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Soleno Therapeutics é uma empresa listada sob o símbolo SLNO (US).

Veja o organograma con seus 17 executivos principais

Biografias mais buscadas da Soleno Therapeutics

• Anish Bhatnagar, Chief Executive Officer and Director
• Birgitte Volck, Director
• Dawn Carter Bir, Director

Criar um alerta
para seguir os movimentos de executivos da Soleno Therapeutics.

Soleno Therapeutics possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of Verve Therapeutics  (publicado em 17 de junho de 2025).
• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Soleno Therapeutics

• Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome – Soleno Therapeutics Inc.
• Soleno Therapeutics to Participate in Fireside Chat at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit – Soleno Therapeutics Inc.
• Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2020 Financial Results – Soleno Therapeutics Inc.
• Soleno Therapeutics Added to Russell 3000® Index – Soleno Therapeutics Inc.
• Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2020 Financial Results – Soleno Therapeutics Inc.
• Soleno Therapeutics Announces Closing of $57.5 Million Public Offering of Common Stock, Including the Full Exercise of Underwriters’ Option to Purchase Additional Shares – Soleno Therapeutics Inc.
• Soleno Therapeutics Added to Russell 3000® Index – Soleno Therapeutics Inc.
• Soleno Therapeutics Announces Closing of $57.5 Million Public Offering of Common Stock, Including the Full Exercise of Underwriters’ Option to Purchase Additional Shares – Soleno Therapeutics Inc.
• Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock – Soleno Therapeutics Inc.
• Soleno Therapeutics Announces Proposed Public Offering of Common Stock – Soleno Therapeutics Inc.
• View more press releases Close

Redes sociais sobre Soleno Therapeutics

• Soleno Therapeutics na Wikipedia, Google News e Yahoo Finance
• Soleno Therapeutics na LinkedIn, Twitter e YouTube